Subtopic Deep Dive

PI3K Activation and AKT Phosphorylation in Cancer
Research Guide

What is PI3K Activation and AKT Phosphorylation in Cancer?

PI3K activation by receptor tyrosine kinases produces PIP3, recruiting and phosphorylating AKT to drive cancer cell survival and proliferation.

Receptor tyrosine kinases activate PI3K, generating PIP3 that binds AKT's PH domain for membrane recruitment and PDK1-mediated Thr308 phosphorylation (Franke et al., 1997; 1686 citations). Full AKT activation requires mTORC2 Ser473 phosphorylation, promoting downstream survival signals (Datta et al., 1999; 4213 citations). PIK3CA mutations hyperactivate this pathway in over 50% of cancers.

Curated Papers

Key Challenges

Why It Matters

Hyperactivated PI3K/AKT signaling drives tumorigenesis in breast, lung, and prostate cancers, with PIK3CA mutations in 30-40% of breast cancers guiding alpelisib approval (Glaviano et al., 2023). AKT phosphorylation inhibits apoptosis via BAD and FOXO inactivation, enabling tumor survival under stress (Datta et al., 1999). mTOR inhibitors induce feedback AKT activation via receptor tyrosine kinases, limiting monotherapy efficacy (O’Reilly et al., 2006; 2531 citations). Isoform-specific AKT inhibitors address resistance in clinical trials (He et al., 2021).

Key Research Challenges

Feedback AKT Activation

mTOR inhibitors upregulate receptor tyrosine kinases, inducing PI3K/AKT activation and therapy resistance (O’Reilly et al., 2006). This feedback limits rapalog efficacy in cancers. Dual PI3K/mTOR blockade is explored but causes toxicity.

Isoform-Specific Functions

AKT1, AKT2, AKT3 isoforms show tissue-specific roles in cancer; AKT1 promotes proliferation, AKT2 metastasis (Datta et al., 1999). Pan-AKT inhibitors cause hyperglycemia; isoform selectivity is needed. Clinical translation lags due to redundancy.

PIK3CA Mutation Heterogeneity

PIK3CA hotspot mutations (E542K, E545K, H1047R) vary by cancer type, affecting inhibitor sensitivity (Glaviano et al., 2023). Resistance emerges via PTEN loss or AKT amplification. Patient stratification requires precise genotyping.

Essential Papers

Cellular survival: a play in three Akts

Soma Datta, Anne Brunet, Michael E. Greenberg · 1999 · Genes & Development · 4.2K citations

The programmed cell death that occurs as part of normal mammalian development was first observed nearly a century ago (Collin 1906). It has since been established that approximately half of all neu...

Upstream and downstream of mTOR

Nissim Hay, Nahum Sonenberg · 2004 · Genes & Development · 4.2K citations

The evolutionarily conserved checkpoint protein kinase, TOR (target of rapamycin), has emerged as a major effector of cell growth and proliferation via the regulation of protein synthesis. Work in ...

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · 2006 · Cancer Research · 2.5K citations

Abstract Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR...

mTOR signaling at a glance

Mathieu Laplante, David M. Sabatini · 2009 · Journal of Cell Science · 2.1K citations

The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and su...

mTOR: a pharmacologic target for autophagy regulation

Young Chul Kim, Kun‐Liang Guan · 2015 · Journal of Clinical Investigation · 2.0K citations

mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregul...

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Carson C. Thoreen, Seong A. Kang, Jae Won Chang et al. · 2009 · Journal of Biological Chemistry · 1.8K citations

PI3K: Downstream AKTion Blocks Apoptosis

Thomas Franke, David R. Kaplan, Lewis C. Cantley · 1997 · Cell · 1.7K citations

Reading Guide

Foundational Papers

Start with Datta et al. (1999; 4213 citations) for AKT isoform survival roles, then Franke et al. (1997; 1686 citations) for PI3K→AKT apoptosis block, followed by O’Reilly et al. (2006; 2531 citations) for clinical feedback mechanisms.

Recent Advances

Glaviano et al. (2023; 1583 citations) reviews targeted therapies; He et al. (2021; 1575 citations) details AKT inhibitor strategies.

Core Methods

Phalloidin staining for PIP3; phospho-AKT flow cytometry; PIK3CA CRISPR editing; alpelisib sensitivity assays in patient-derived xenografts.

How PapersFlow Helps You Research PI3K Activation and AKT Phosphorylation in Cancer

Discover & Search

Research Agent uses citationGraph on Datta et al. (1999; 4213 citations) to map AKT isoform papers, exaSearch for 'PIK3CA mutation AKT phosphorylation breast cancer', and findSimilarPapers to uncover O’Reilly et al. (2006) feedback mechanisms.

Analyze & Verify

Analysis Agent runs readPaperContent on O’Reilly et al. (2006) to extract RTK upregulation data, verifyResponse with CoVe against Hay & Sonenberg (2004), and runPythonAnalysis to plot phosphorylation time-courses from supplementary figures using matplotlib, with GRADE scoring evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in isoform-specific inhibitor trials via contradiction flagging between He et al. (2021) and Glaviano et al. (2023), then Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations for 20+ references, and latexCompile for camera-ready reviews; exportMermaid visualizes PI3K→PIP3→AKT cascades.

Use Cases

"Extract and plot AKT phosphorylation kinetics from mTOR inhibitor papers"

Research Agent → searchPapers('mTOR inhibition AKT activation') → Analysis Agent → readPaperContent(O’Reilly 2006) → runPythonAnalysis(pandas/matplotlib on Supp Fig 2 data) → researcher gets time-series plot with statistical fits.

"Write LaTeX review on PI3K feedback loops with citations"

Synthesis Agent → gap detection(Glaviano 2023 + Hay 2004) → Writing Agent → latexEditText(structured review) → latexSyncCitations(15 papers) → latexCompile(PDF) → researcher gets publication-ready manuscript with pathway figure.

"Find GitHub code for PI3K/AKT simulation models"

Research Agent → searchPapers('PI3K AKT kinetic model') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets ODE simulation code linked to Sabatini 2009 pathway data.

Automated Workflows

Deep Research workflow scans 50+ PI3K/AKT papers via citationGraph from Datta 1999, producing structured reports with GRADE-scored evidence on mutation prevalence. DeepScan applies 7-step CoVe to verify feedback claims in O’Reilly 2006 against Hay 2004. Theorizer generates hypotheses on AKT3-specific inhibitors from isoform papers.

Try Doxa for PI3K Activation and AKT Phosphorylation in Cancer Research

Frequently Asked Questions

What defines PI3K activation in cancer?

Receptor tyrosine kinases recruit PI3K to generate PIP3, enabling AKT PH-domain binding and phosphorylation at Thr308 by PDK1 (Vanhaesebroeck & Alessi, 2000).

What are key methods to study AKT phosphorylation?

Western blotting detects p-AKT Ser473/Thr308; CRISPR screens identify regulators; PIK3CA mutant cell lines test inhibitors (Franke et al., 1997; O’Reilly et al., 2006).

What are seminal papers?

Datta et al. (1999; 4213 citations) defined AKT isoforms' survival roles; O’Reilly et al. (2006; 2531 citations) revealed mTOR feedback AKT activation.

What open problems exist?

Overcoming isoform redundancy, feedback resistance, and PIK3CA mutation-specific therapies; dual PI3K/AKT inhibitors show promise but toxicity issues persist (He et al., 2021).